HIV-1 Infection Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight

DelveInsight's, "HIV-1 Infection Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in HIV-1 Infection pipeline landscape. It covers the HIV-1 Infection Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HIV-1 Infection Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the HIV-1 Infection Pipeline? Click here to explore the therapies and trials making headlines @ HIV-1 Infection Pipeline Outlook Report- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the HIV-1 Infection Pipeline Report
• On 26 September 2025, Gilead Sciences announced a clinical study are to learn how Bictegravir/Emtricitabine/Tenofovir Alafenamide fixed dose combination (FDC) interacts with the body, confirm the dose, and also to learn more about the safety and tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide FDC in adolescents and children with HIV-1.
• On 16 September 2025, CytoDyn Inc. conducted a clinical trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART (antiretroviral therapy) during the initial one-week treatment period, and in combination with Optimized Background Therapy during the subsequent 24-week treatment period.
• DelveInsight's HIV-1 Infection Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for HIV-1 Infection treatment.
• The leading HIV-1 Infection Companies such as United BioPharma, Gilead Sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics and others.
• Promising HIV-1 Infection Therapies such as Romidepsin, Maraviroc, TMB-365, Lenacapavir, PRO 140, Doravirine, Darunavir, Ritonavir, Etravirine (TMC125) and others.

Want to know which companies are leading innovation in HIV-1 Infection? Dive into the full pipeline insights @ HIV-1 Infection Clinical Trials Assessment- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The HIV-1 Infection Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The HIV-1 Infection Pipeline Report also highlights the unmet needs with respect to the HIV-1 Infection.

HIV-1 Infection Overview
HIV-1 is the most common type of Human Immunodeficiency Virus. It attacks the body's immune system. The virus destroys CD4 cells. CD4 cells help the body to fight infections. HIV-1 can severely damage immune system and lead to Acquired Immune Deficiency Syndrome (AIDS). Infection with HIV type 1 (HIV-1) typically occurs across mucosal surfaces or by direct inoculation. The virus first encounters dendritic cells (DCs), which subsequently facilitate spread of HIV-1 to CD4+ T lymphocytes. Human Immunodeficiency virus 1 is transmitted in bodily fluids that include: blood, semen, vaginal and rectal fluids, breast milk.

HIV-1 Infection Emerging Drugs Profile
• UB421: United BioPharma
UB-421 is an experimental HIV antibody, under development in phase III by United Biomedical, Inc. (UBI), headquartered in Hauppauge, New York, U.S. for use in the treatment of HIV infection. By blocking the CDR2 domain of the CD4 receptor of the virus, it prevents initial viral attachment to the host T cell and entry into the host immune cell via a competitive inhibition mechanism.

• Islatravir (MK-8591): Merck Sharp & Dohme
Islatravir belongs to a group of HIV drugs called nucleoside reverse transcriptase translocation inhibitors (NRTTIs). NRTTIs use several different methods to block an HIV enzyme called reverse transcriptase. By blocking reverse transcriptase, NRTTIs prevent HIV from multiplying and can reduce the amount of HIV in the body. Currently, it is being investigated in Phase III as a potential treatment for Hiv 1 infections.

• PRO140: CytoDyn Inc.
Leronlimab (Pro 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated in Phase II as a potential treatment for HIV1 infections.

If you're tracking ongoing HIV-1 Infection Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ HIV-1 Infection Treatment Drugs- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The HIV-1 Infection Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of HIV-1 Infection with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HIV-1 Infection Treatment.
• HIV-1 Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HIV-1 Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HIV-1 Infection market.

HIV-1 Infection Companies
United BioPharma, Gilead Sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics and others.

HIV-1 Infection Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Oral
• Intravenous
• Intramuscular
• Subcutaneous
• Molecule Type

HIV-1 Infection Products have been categorized under various Molecule types such as,
• Monoclonal Antibody
• Peptides
• Small molecule
• Product Type

From emerging drug candidates to competitive intelligence, the HIV-1 Infection Pipeline Report covers it all - check it out now @ HIV-1 Infection Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HIV-1 Infection Pipeline Report
• Coverage- Global
• HIV-1 Infection Companies- United BioPharma, Gilead Sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics and others.
• HIV-1 Infection Therapies- Romidepsin, Maraviroc, TMB-365, Lenacapavir, PRO 140, Doravirine, Darunavir, Ritonavir, Etravirine (TMC125) and others.
• HIV-1 Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HIV-1 Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the HIV-1 Infection Treatment landscape in this detailed analysis @ HIV-1 Infection Emerging Drugs and Major Players- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Human Immunodeficiency Virus Type 1 (HIV-1) Infection - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Collaboration Deals
9. Late Stage Products (Phase III)
10. UB421: United BioPharma
11. Drug profiles in the detailed report.....
12. Mid Stage Products (Phase II)
13. PRO140: CytoDyn Inc.
14. Drug profiles in the detailed report.....
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report.....
18. Inactive Products
19. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Companies
20. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Products
21. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Unmet Needs
22. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Market Drivers and Barriers
23. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Future Perspectives and Conclusion
24. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Analyst Views
25. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.